Rossari Biotech Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/42lvvjnuob6w1c570degs9a8.pdf

Key Takeaways


The Institutional & B2C Bet

Chari: "When we go to a customer like a Taj Hotel or ITC Hotel or a Marriott or a Hyatt or a Hilton, we need to be a one-stop shop. Otherwise, they will not entertain us."

Ethylene Oxide: The Constraint and the Workaround


CAPEX: Backward Integration and New Chemistries


Cost Structure: The Investment Phase

Sablok: "So, my take is that the current quarterly run rate, we should be around that for the next year. So, employee cost, my expectation is that we will be at that Rs. 30- Rs. 35 crore run rate. And the other expenses should be around Rs. 65 crore plus-minus per quarter."

Exports and Geopolitical Positioning

Chari: "At the moment, we are not clear on what the future is. The skies are not clear. The path is not clear. We are not able to tell you."

Margin Outlook and Recovery Path

Sablok: "It's not proper to read it in a manner that Rs. 124 crore of additional sales have brought in Rs. 10 crore of dip in the EBITDA."

Guidance & Commitments

CommitmentSpecificsTimeline
Dahej and Unitop expansionsCommissioning as per revised planQ2 FY26
New CAPEX (₹192 crore)Phased commissioning of backward integration and new chemistry projectsBy Q4 FY26
Continuous Ethoxylation plantStart of operations, enabling new higher-margin chemistriesQ2 FY26
HPPC Ethoxylate growthLow double-digit growth (~10%), contingent on higher EO availability from RelianceFY26
Overall revenue growthAt least mid-teens levelFY26
Core business EBITDA margin14.5%-15% range (shorn of consumer business)FY26
Overall company EBITDA margin13%-13.5% targetFY26
Institutional & Consumer (Buzil) EBITDALow single-digit positive EBITDA on an annualized basisFY26
Employee cost run rate₹30-35 crore per quarterFY26
Other expenses run rate~₹65 crore per quarterFY26
New CAPEX asset turns2x-3x on backward integration projectsPost-commissioning
Tissues and foils productionMove most into in-house production facilityOver the current year (FY26)

Key Metrics

MetricQ4 FY25
Revenue from operations₹579.6 crore, up 22.6% YoY
EBITDA₹69.5 crore, up 9.3% YoY
EBITDA margin12%, compared to 13.5% in Q4 FY24
Full-year FY25 revenue from operations₹2,080 crore, up 13.6% YoY
Full-year FY25 EBITDA₹265.1 crore, up 6.1% YoY
Full-year FY25 EBITDA margin12.7%, compared to 13.6% in FY24
Institutional and B2C business FY25 revenue₹299 crore, up 67% YoY
Adjusted EBITDA margin, core business (ex-Institutional and B2C) FY25~15%
Exports growth FY2527%, presence expanded to over 70 countries
Q4 FY25 exports₹162 crore, compared to ₹127 crore in Q4 FY24
Total CAPEX approved~₹192 crore, covering expansions at subsidiaries and Rossari Biotech, phased commissioning by Q4 FY26
Net debt, FY25 end₹70 crore
Average cost of debt8%
Dividend recommended per share FY25₹0.50
Capacity utilization, EthoxylationCompletely utilized at Unitop and Tristar
Capacity utilization, formulation side50%–55%
Employee cost expected quarterly run rate₹30–35 crore
Other expenses expected quarterly run rate₹65 crore plus-minus
Headcount increase140–145 people between the two years
Overall company EBITDA margin target13%–13.5%
Core business EBITDA margin target14.5%–15%
Annualized top line growth target~15%
Buzil gross margins26%–27% range for FY25 and FY24
Working capital improvement2 days compared to last year
Receivables reduction2 days